Ayahuasca for Health & Longevity - Quick Reference Sheet

Ayahuasca for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A plant brew: one ingredient alters perception and thought, a second keeps it from being broken down in the gut. Its clearest effect is a rapid mood lift in hard-to-treat depression, though a later comparison suggests that shrinks once expectation is accounted for. Vomiting and raised blood pressure are near-universal; serious harm concentrates where screening is absent. (Full Review)

Protocol

Traditional Amazonian ceremonial protocol
100–200 mL cup
20–60 mg DMT, 100–250 mg harmine; 4–6 h sessions on 2–4 nights across a 5–10 day retreat. Trials dose at 1 mL/kg.
Single versus split dosing
Split, top-up at 60–90 min
Ceremonial standard; the more conservative route for a first-time drinker. Clinical protocols use a single fixed dose.
Best time of day
Dusk, or daytime
Night sessions are more intense with worse sleep; day sessions, used in trials, are more manageable with better recovery.
Time to effect
Mood changes
Within 24 hours
Where they occur. The trial signal was measured over 7 to 21 days and attenuated thereafter.
Wellbeing, mindfulness, behaviour
1 to 6 months
Assessed at 1, 3, and 6 months in the prospective literature, attenuating over that window.
Acute effects
30 to 60 minutes
Peak at 1–2 h, resolve over 4–6 h; interaction window extends at least 24 h beyond feeling normal.

Benefits

Contraindications
  • Personal or first-degree-family history of schizophrenia, schizoaffective disorder, or bipolar I disorder
  • Current psychotic symptoms
  • Uncontrolled hypertension above 160/100 mmHg
  • Myocardial infarction within 6 months, unstable angina, or NYHA Class III–IV heart failure
  • Long QT syndrome with a QTc above 500 ms
  • Uncontrolled epilepsy
  • Hepatic impairment of Child-Pugh Class B or C
  • Pregnancy and breastfeeding
  • Active eating disorder with purging behaviour
  • Unable or unwilling to complete a supervised washout from a serotonergic medication
Key Interactions
  • Serotonin reuptake inhibitors (fluoxetine, sertraline, escitalopram): 2-week washout, 5–6 weeks for fluoxetine
  • Serotonin-noradrenaline reuptake inhibitors (venlafaxine, duloxetine) and tricyclic antidepressants (amitriptyline): 2-week washout
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide), linezolid: 2-week washout
  • Serotonergic opioids and cough preparations (tramadol, pethidine, dextromethorphan, fentanyl)
  • Stimulants and empathogens (amphetamine, methylphenidate, cocaine, MDMA); synephrine thermogenics
  • Triptans (sumatriptan, rizatriptan), decongestants (pseudoephedrine, phenylephrine): 24 h either side; lithium
  • 5-HTP, L-Tryptophan, St. John's wort: stop 2 weeks before; SAMe: 1 week; Syrian rue
  • Kambo and tobacco-based purgatives
  • High-tyramine foods (aged cheeses, cured meats, soy sauce, tap beer, yeast extracts): 24 h either side

Risk & Side Effects

  • High: Nausea, vomiting, and diarrhea; transient blood pressure and heart rate elevation; acute psychological distress
  • Medium: Serotonin toxicity when combined with serotonergic drugs; prolonged psychiatric complications; headache and post-session fatigue
  • Low: Manic or hypomanic episodes; seizures; hallucinogen persisting perception disorder; deaths in retreat settings; harms arising from unregulated settings
  • Speculative: Reproductive and developmental toxicity; hepatotoxicity; cardiac valvulopathy from repeated 5-HT2B activation

Monitoring

Marker Target Why
Blood pressure < 120/80 mmHg Determines whether the acute 10–25 mmHg systolic rise is safe
Resting heart rate 50–70 bpm Baseline for the acute heart-rate rise; flags autonomic strain
Electrocardiogram, QTc interval < 440 ms men, < 460 ms women Excludes the electrical-recovery abnormality behind adrenaline-driven arrhythmia
hs-CRP < 0.5 mg/L Baseline inflammation; the marker that tracked antidepressant response
Serum potassium 4.0–4.5 mmol/L Vomiting-driven loss is the main arrhythmia and seizure-threshold risk
Serum magnesium (RBC) 5.0–6.5 mg/dL Same rationale; red-cell magnesium reflects stores better than serum
ALT and AST < 25 U/L both Hepatic capacity to clear β-carbolines; screens for occult liver disease
eGFR > 90 mL/min/1.73m² Fluid and electrolyte handling under vomiting-driven loss
Fasting glucose and HbA1c < 90 mg/dL; < 5.3% Metabolic baseline; pre-ceremony fasting is poorly tolerated with unstable blood sugar control
TSH 0.5–2.0 mIU/L Untreated thyroid dysfunction mimics and amplifies anxiety and cardiovascular response
CYP2D6 genotype Normal metaboliser status Identifies poor metabolisers reaching far higher harmine exposure from the same cup
PHQ-9 and GAD-7 questionnaire scores PHQ-9 < 5; GAD-7 < 5 The only measures verifying a mood or anxiety benefit

Cadence: Blood pressure and resting heart rate on session morning and at 24 h; potassium and magnesium at 48 h after prolonged vomiting or a multi-night format; PHQ-9 and GAD-7 at 1 week, 4 weeks, and 3 months; hs-CRP at 4 weeks; liver enzymes, kidney function, and the full panel at 6 to 12 months for anyone drinking more than twice a year.

Qualitative Assessment

  • Rumination frequency: whether self-critical thought loops occur less often and are easier to step out of
  • Emotional range and reactivity: whether flattened responses return and reactions are less automatic; blunting would be a warning sign, not a benefit
  • Sleep quality: subjective restfulness and time to fall asleep at 4 weeks and beyond, distinct from the two disrupted nights around the session
  • Behavioural change that persists: whether alcohol intake, training consistency, or relationship patterns have shifted at 3 months
  • Cognitive clarity and flexibility: whether problem-solving feels less rigid and attention is intact; persisting fogginess, visual disturbance, or unreality beyond a week warrants clinical assessment
  • Absence of warning signs: no persisting derealisation or depersonalisation, no reduced sleep need with elevated mood and accelerated thinking, no intrusive imagery